High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.

School of Medicine, University of California, San Francisco 94143-0324, USA.
Biology of Blood and Marrow Transplantation (Impact Factor: 3.35). 09/2000; 6(5):496-505. DOI: 10.1016/S1083-8791(00)70020-6
Source: PubMed

ABSTRACT The role of high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell rescue in breast cancer is still controversial. We analyzed the outcomes of 1111 consecutive patients with histologically proven breast cancer who underwent HDCT at 5 major California medical centers. The overall treatment-related mortality (TRM) was 2.3%. TRM was not influenced by disease stage or the HDCT regimen delivered, but it was influenced by hematopoietic graft source. The TRM was 6.1% when bone marrow with or without blood stem cells was used, but only 1.4% when blood stem cells alone were used (P < .001). With a median follow-up of 2.8 years (range, 0.1-8.2 years) after HDCT and autologous hematopoietic stem cell rescue, the estimated 5-year event-free survival (EFS) and overall survival (OS) for stage II/IIIA patients with > or =10 involved axillary lymph nodes were 67% and 76%, respectively. Patients with metastatic breast cancer (MBC) (median follow-up, 1.9 years [range, 0.03-8.3 years]) achieving a complete response (CR) to conventional-dose chemotherapy or rendered to a "no evidence of disease" status before HDCT had significantly better estimated 5-year EFS and OS (28% and 57%, respectively) than those achieving a partial response before HDCT (19% and 27%, respectively; P < or = .0001). Our data suggest that HDCT with hematopoietic stem cell rescue is safe and can be beneficial to patients with high-risk primary breast cancer and for those with MBC achieving CR/no evidence of disease.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biol Blood Marrow Transplant 2000;6(5):469-75.
    Biology of Blood and Marrow Transplantation 02/2000; 6(5):469-75. DOI:10.1016/S1083-8791(00)70018-8 · 3.35 Impact Factor
  • Source
    Eye 01/2002; 15(Pt 6):695-707. DOI:10.1038/eye.2001.233 · 1.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The relative efficacy of high-dose chemotherapy (HDC) compared to standard treatment for high-risk primary (HRPBC) or metastatic breast cancer (MBC) constitutes an area of intense controversy among the medical oncology community. A number of randomized trials have been conducted to address this issue. In most cases, the results of these trials are premature and contradictory. Furthermore, they have often been interpreted, incorrectly in this author's judgment, as proof of lack of benefit of HDC. The results of studies published in peer-reviewed medical journals or presented in scientific meetings are discussed. In some cases, the status of the studies was determined through direct communication with the trial's principal investigator. The encouraging results of phase II trials suggested a benefit for HDC in important categories of patients with breast cancer. It has been argued that selection of patients might have been a critical factor in those studies. The results, in most cases preliminary, of numerous randomized trials in metastatic and high-risk primary disease cannot offer a definitive answer to this crucial question as of yet. Important concepts in the interpretation of these studies, such as size and statistical power, length of follow-up, magnitude of clinical benefit, and broad applicability of the results, are discussed in this review. The role of HDC for HRPBC or MBC patients remains undefined. Longer follow-up and mature analyses of the randomized trials are necessary before definitive conclusions are drawn. In the meantime, it is imperative that research continues, to enhance the efficacy of the procedure through innovative strategies.
    Haematologica 03/2003; 88(2):201-11. · 5.87 Impact Factor
Show more


Available from